New small-molecule drug design strategies for fighting resistant influenza A
نویسندگان
چکیده
Influenza A virus is the major cause of seasonal or pandemic flu worldwide. Two main treatment strategies-vaccination and small molecule anti-influenza drugs are currently available. As an effective vaccine usually takes at least 6 months to develop, anti-influenza small molecule drugs are more effective for the first line of protection against the virus during an epidemic outbreak, especially in the early stage. Two major classes of anti-influenza drugs currently available are admantane-based M2 protein blockers (amantadine and rimantadine) and neuraminidase (NA) inhibitors (oseltamivir, zanamivir, and peramivir). However, the continuous evolvement of influenza A virus and the rapid emergence of resistance to current drugs, particularly to amantadine, rimantadine, and oseltamivir, have raised an urgent need for developing new anti-influenza drugs against resistant forms of influenza A virus. In this review, we first give a brief introduction of the molecular mechanisms behind resistance, and then discuss new strategies in small-molecule drug development to overcome influenza A virus resistance targeting mutant M2 proteins and neuraminidases, and other viral proteins not associated with current drugs.
منابع مشابه
Antifungal drug resistance of yeasts in dermatology: mechanisms, epidemiology and clinical impact
Superficial dermatophytoses are among the most common infectious disease. The most commonly used antifungal categories reazoles, polyenes and echinocandins. Due to the limited number of available antifungal drugs, toxicity and the emergence of resistant (intrinsic or acquired) strains, antifungal strategy needs to be developed. Recently the researchers try to find alternative antifungal agents....
متن کاملشناسایی ویروسهای آنفلوانزای A/H3N2 مقاوم به اسلتامیویر با تست Real-time RT- PCR
Background: Currently, with increasing risk of influenza A virus epidemics, a lot of studies have been performed. Oseltamivir or Tamiflu (the neuraminidase (NA) inhibitor) is one of the effective drugs for preventing and treatment of these viruses. The H274Y mutation is from the most important drug resistant factors in influenza A viruses. The aim of this study was detection of Oseltamivir...
متن کاملتغییرات ژنتیکی ویروس و فرار از سامانه ایمنی، چالشهای پیشرو علیه آنفلوآنزا: مقاله مروری
The spread of influenza viruses in multiple bird and mammalian species is a worldwide serious threat to human and animal populations' health and raise major concern for ongoing pandemic in humans. Direct transmission of the avian viruses which have sialic acid specific receptors similar to human influenza viruses are a warning to the emergence of a new mutant strain that is likely to share mole...
متن کاملStructure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo Œ PLOS Currents Influenza
We report preliminary results and a summary of a bottom-up approach to identify new, active, nontoxic, small-molecule antivirals designed to have ? novel mechanism of action. We employed the procedure to identify 3-mercapto-1,2,4-triazoles derivatives as potential NP inhibitors in silico and subsequently demonstrated the in vitro efficacy of the molecules against various strains of the influenz...
متن کاملStructure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo
We report preliminary results and a summary of a bottom-up approach to identify new, active, nontoxic, small-molecule antivirals designed to have а novel mechanism of action. We employed the procedure to identify 3-mercapto-1,2,4-triazoles derivatives as potential NP inhibitors in silico and subsequently demonstrated the in vitro efficacy of the molecules against various strains of the influenz...
متن کامل